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Summary





Metallo--lactamases (MBLs) belong to class B of the -lactamases  ADDIN EN.CITE [1-3]. All MBLs exhibit the α/α sandwich fold [4] and unlike the enzymes of other classes (A, C and D), which all contain a nucleophilic serine residue in their active site, the MBLs utilize zinc to perform hydrolysis  ADDIN EN.CITE [5, 6]. The heterogeneous class of MBLs is further divided into 3 groups (B1, B2 and B3) according to substrate specificity and sequence similarity  ADDIN EN.CITE [7]. Subclass B2 has a narrow substrate spectrum limited to carbapenems  ADDIN EN.CITE [8] whereas subclasses B1 and B3 have broad substrate spectra, with B3 showing preferential activity for cephalosporins  ADDIN EN.CITE [9, 10].
Subclass B1 contains IMP- and VIM-variants as well as NDM-1, which are encoded by mobile genetic elements, posing the greatest threat of all the MBLs. Also present in the group are the well characterized MBLs of Bacillus cereus (BcII) which was the first to be discovered [11] and Bacteroides fragilis (CcrA) [12]. Subclass B2 contains the very similar Aeromonas enzymes, CphA [13] and ImiS [14].
Subclass B3 consists of the L1  ADDIN EN.CITE [15], FEZ-1  ADDIN EN.CITE [16], GOB-type enzymes  ADDIN EN.CITE [17, 18], Thin-B  ADDIN EN.CITE [19], CAU-1  ADDIN EN.CITE [20], Mbl1b  ADDIN EN.CITE [21], BJP-1  ADDIN EN.CITE [22] and CAR-1  ADDIN EN.CITE [23]. However, only the first three are clinically relevant. L1 exhibits the broadest substrate range of the MBLs and is uniquely tetrameric  ADDIN EN.CITE [9, 24, 25]. FEZ-1 shares 29.7% sequence identity with L1 but has a more limited substrate profile, with a strong preference for cephalosporins  ADDIN EN.CITE [16, 26]. GOB-type enzymes include 18 variants including GOB-1 the first isolated GOB enzyme  ADDIN EN.CITE [17]. GOB-1 is from Elizabethkingia meningoseptica (formerly Chryseobacterium meningosepticum) the pathogen responsible for neonatal meningitis, and also found to attack immunocompromised patients. It shares sequence identities of 28% with L1 and 43% with FEZ-1 (computation performed at the SIB using the BLAST network service). The GOB-18 variant studied by Moran-Barrio differs from GOB-1 by just three residues Phe94, Ala137 and Asp282 far from the active site  ADDIN EN.CITE [18].
The three subclasses of MBLs also differ in their zinc dependency  ADDIN EN.CITE [7]. Subclass B1 enzymes can be active with one or two zinc ions in their active sites, whereas those of subclass B3 contain two zinc ions  ADDIN EN.CITE [27, 28]. In contrast subclass B2 enzymes are active with one zinc ion and are inhibited by the binding of a second zinc  ADDIN EN.CITE [29]. The crystal structures of the MBLs highlight two sites of zinc coordination. The first zinc site in classes B1 and B3 (HHH) is composed of residues His116, His118 and His196. The sole exceptions to this are the GOB enzymes, which have a glutamine at position 116. In subclass B2, position 116 is occupied by an asparagine residue  ADDIN EN.CITE [7] and this was previously thought to be one of the residues to which the inhibitory zinc binds. However, the recent structure of the subclass B2 CphA showed that the second inhibitory zinc ion was just bound to the two remaining histidines, His196 and His118  ADDIN EN.CITE [30]. The second zinc site of subclass B1 is identical to the first site of subclass B2 and consists of Asp120, Cys221 and His 263 (DCH), whereas in subclass B3 Cys221 is replaced by His121 (DHH) as a zinc ligand  ADDIN EN.CITE [7, 15, 26]. 





Construction of expression vector and preliminary expression experiments
The pGB1 expression vector was constructed to include the enzyme’s own signal peptide and stop codon. The preliminary expression trials showed that the best yield was obtained in Terrific Broth medium in the absence of Isopropyl β-D-1-thiogalactopyranoside (IPTG) with incubation at 28 C for 24 hr and showed no noticeable expression of the unprocessed precursor species. Under these conditions, GOB-1 represented only a low percentage of cell protein but significantly more than with the pBS3 plasmid, previously described in Bellais et al.  ADDIN EN.CITE [17]. Unfortunately with the crude extracts derived from the expression trials activation by the substrate was observed which made quantification difficult. This prevented an accurate determination of the quantity of GOB-1 present in the crude extract but an estimate using the highest rate suggested that about 40 mg of GOB-1 was produced per liter of culture.

Purification of wild-type GOB-1
The reported purifications of several metallo--lactamases utilize an S-Sepharose column as the first purification step. When applied to GOB-1 this step yielded an enzyme with few contaminants. The second step was an UNO S12 column and allowed the removal of some impurity but was not sufficient to reach homogeneity. A further purification step on a molecular sieve removed the two remaining contaminants of lower molecular masses. After the three purification steps, 7.6 mg of GOB-1 were produced showing no contaminants by SDS PAGE. The use of the molecular sieve column also confirmed a 30 kDa MM and thus a monomeric structure as shown by Bellais et al  ADDIN EN.CITE [17]. 

Mass Spectrometry and N-terminal sequencing of wild-type GOB-1
The ESI-TOF MS spectra of the denatured protein (data not shown) showed two peaks indicating the presence of two proteins separated by 299 Da. The native ESI-TOF MS spectra (Figure 1) also showed two peaks separated by 300 Da. This showed the presence of two proteins which could not be separated during purification and by SDS PAGE, and which contained the same amount of zinc. This implied that both proteins were GOB-1 although one was modified in some way, most likely by incorrect cleavage of the signal peptide to create -lactamase ragged ends. 
The mass difference between the native and denatured spectra corresponds to the mass of zinc in the enzyme (Table 1). The result suggests that the native protein contains 2 zinc ions per wild-type molecule. The other members of subclass B3, both L1 and FEZ-1 also contain 2 zinc ions in their active sites  ADDIN EN.CITE [9, 10].

To verify the hypothesis that GOB-1 has ragged ends (not a unique phenomenon with respect to MBLs [32]), the N-terminus of the enzyme was sequenced. The presence of two N-terminal sequences QVVKE and LNAQV confirmed that the signal peptide was cleaved at 2 positions.
In addition, a sample was digested using trypsin and the molecular mass of the resulting peptides was measured by MALDI TOF MS (Figure 2). A theoretical digestion of GOB-1 was performed using Peptide Mass on the expasy.org website.  The sequence coverage given by the peptides produced by the tryptic digestion of GOB-1 is given as supplementary material (Fig. S1). All the peaks detected by MALDI TOF MS could be identified as peptides produced by the tryptic digestion with three exceptions. The peak at 1598 (Figure 2) is not a theoretical product of digestion, it does, however, correspond to the mass of the N-terminal peptide (1299 kDa) plus 298 Da, a value which in turn corresponds to the mass of the last 3 amino acids of the signal peptide, LNA. Another of the unidentified peptides, of mass 1282, is the mass of the N-terminal peptide less 17 Da, suggesting that the N-terminal glutamine residue has undergone cyclisation into pyro-glutamate with the loss of NH3. The third peak at 1453 kDa could not be explained and does not correspond to digestion of the enzyme or unprocessed precursor species.


Mutation of the glutamine 116 residue
At position 116, GOB-1 has a glutamine rather than a histidine residue like other members of subclass B3 (or indeed subclass B1). To investigate the effect of this residue, it was mutated to histidine, asparagine (the amino acid at position 116 in subclass B2) and, as a control, alanine, giving the Q116H, Q116N and Q116A mutants respectively.
The best purification method found for the mutant enzymes was to use the S- Sepharose column, followed by a 5 ml Econo-Pac CHT-II cartridge. The remaining impurities were removed in a third purification step on an S-Source column. This last step produced two elution peaks for each enzyme. In each case, the mass difference between the two elution peaks was found to be 18 Da by ESI-TOF MS (Figure 3) and the highest peak corresponded to the theoretically calculated mass. In consequence, as the purified wild type, the N-terminal residue of the mutants has undergone partial cyclisation. The protein of highest molecular mass (Table 1) was used in all experiments.

Mass Spectrometry of GOB-1 mutants
Native ESI-TOF MS spectra of the mutants were obtained. Although Figure 4 reveals the presence of many salt peaks, the spectra suggest that both Q116N and Q116A contain 1 zinc ion per molecule. This is confirmed by the ICP/MS results (see below). Therefore the mutation of the glutamine residue at position 116 results in the loss of zinc from the corresponding site of the enzyme under MS conditions. Q116H, like the wild-type, contains 2 zinc ions (Tables 1 and 2). 

Determination of the zinc and iron contents using ICP/MS
In contrast to the wild-type and Q116H enzymes, ICP/MS failed to highlight the binding of two zinc ions by the Q116A and Q116N enzymes (Table 2). Moreover, the ICP/MS discarded the presence of bound iron in all the enzymes. 

Kinetic study
Before the kinetic characterization of GOB-1, the optimum concentration of ZnCl2 in the buffer was determined. At the three concentrations of imipenem tested, addition of Zn2+ in the buffer did not significantly modify the activity. However, 50 M ZnCl2 gave a slightly higher rate of hydrolysis. Consequently, 50 M ZnCl2 was thereafter added to the buffer.
The steady-state kinetic parameters of the wild-type and mutant GOB-1 enzymes were measured with the β-lactam substrates benzylpenicillin, cefoxitin, cephalothin, imipenem, meropenem and nitrocefin, both in the presence and absence of added zinc. The results are shown in Table 3. The wild-type enzyme hydrolyzed all the substrates very efficiently, almost independently of the zinc concentration in the buffer, showing no strong preference for any type of β-lactams. Our results support those previously reported for GOB-1  ADDIN EN.CITE [17] with the enzyme showing the highest rate of substrate turnover with penicillin (kcat 630 s-1) and the highest kcat /KM value with meropenem (8.0 µM-1s-1). 
The mutations of the glutamine residue 116 significantly affected the catalytic ability of the enzyme, as would be expected for a zinc binding residue. In the absence of added zinc, the activity was decreased 60-600 fold when the residue was mutated to the non-chelating alanine (Q116A). However, the resulting enzyme was not completely inactive and whilst the kcat values were dramatically decreased, the Km values were very similar. Activity was not restored by the addition of 50 µM zinc. Indeed, although slightly increased kcat values (e.g. 4.6 fold for imipenem), the kcat/Km values nevertheless slightly decreased due to the large increase of KM values (34 fold for imipenem). 
The effects of the Q116N mutation were slightly different. The results in Table 2 show an important loss of activity in the absence of zinc (160 to 1500 times), mainly due to a decrease of kcat values. The KM values remained quite similar (meropenem, cefoxitin), slightly (imipenem, benzylpenicillin) or significantly increased (nitrocefin, cephalothin). In contrast to the Q116A mutant, the activity of the Q116N mutant increased when 50 µM zinc was present in the buffer (Q116N is then only 1.3 to 110 fold less active than the wild-type). KM values were similar to that of the wild-type (with the exception of nitrocefin). Initial hydrolysis rates of 100 µM nitrocefin were measured in presence of increasing zinc concentrations (0, 1, 2.5, 5, 10, 25, 50, 100, 250, 500 and 1000 µM). This experiment showed that the maximal rate is obtained at a 50 µM zinc concentration and is constant up to the highest tested concentration. The apparent dissociation constant for the second zinc ion (KD2) determined from this graph was 2.5 ± 0.3 µM (supplementary material, Fig. S2).
The effects of the Q116H mutation were less drastic. The activity decrease in comparison to the wild-type enzyme was only 2.1 to 74 fold. The kcat values decreased only 1.9 (for benzylpenicillin) to 50 fold (for imipenem). The KM values significantly increased for all the substrates but meropenem and cefoxitin. Q116H showed similar kcat and KM values in the presence of 50 µM zinc. 

Apo-GOB-1 and the remetallated form
The GOB-1 apoprotein was devoid of -lactamase activity that could be recovered by addition of Zn(II). Remetallated GOB-1 bound 2 equivalent of zinc as shown by ICP/MS and mass spectrometry (supplementary material, Fig.S3). However, its activity was only 60 % of that of the enzyme as isolated. Addition of zinc (50 µM, 100 µM or 1 mM) to the reaction medium did not modify significantly this activity.

Inactivation by metal chelator





The MBL GOB-1 is a very efficient enzyme, which hydrolyzes the 6 tested β-lactams with kcat/KM values above 106 M-1s-1. All the kcat/KM values reported here are slightly higher (between 1.5 and 10 fold) than those previously published by Bellais et al.  ADDIN EN.CITE [17] probably because of the higher protein purity. The kinetic parameters determined here for the GOB-1 enzyme are also similar to those previously determined for the GOB-18 variant  ADDIN EN.CITE [18].
The mutants of GOB-1 generated by site-directed mutagenesis of Gln116 exhibit a loss of activity which cannot be corrected by addition of zinc. The Q116H mutant and the wild-type enzyme both contain 2 zinc ions in the active site and therefore show little difference upon the addition of further zinc. However, the mutant exhibited significantly less activity than the wild-type GOB-1 (kcat shows a 2 to 50 fold decrease, dependent upon which substrate is examined) and increased Km values suggesting than the steric effect of the larger, less flexible histidine residue hinders the positioning of the substrates in the active site. Another possibility would be the creation of a modified zinc position in the recreated HHH site leading to a decreased efficiency. However, since all other B1 and B3 enzymes include a histidine at position 116, this will remain speculation until the structure of the GOB-1 active site is directly determined. 
In contrast to the Q116H mutant, the presence of an alanine or an asparagine residue at position 116 decreased the ability of the latter mutants to chelate a zinc ion in the AHH or NHH site. Indeed, in absence of added zinc ([Zn] < 0.5 µM), these mutants were under a mono-zinc form while the wild-type GOB-1 is already in a di-zinc form. The Km values determined in these conditions for the Q116A mutant are very similar to those corresponding to the wild-type enzyme. This suggests that the Q116A mutation, which affects the metal content, does not affect the binding of the substrates. A similar behaviour is observed for the carbapenemase activity of the Q116N mutant.
This decreased ability to chelate a second zinc is also reflected by the KD2 value determined for the Q116N mutant. These results prove that Q116 plays a role in the binding of the zinc ion in the QHH site. The kcat and kcat/Km values of the Q116A and Q116N mutants were strongly decreased (kcat shows an 11 to 284 fold decrease for Q116A and a 23 to 227 fold decrease for Q116N compared to that of the wild-type) and cannot be restored by the addition of zinc. Nevertheless, the activity of the Q116N mutant increased with increasing zinc concentration in the buffer.  This contrasts with the subclass B2 enzymes, which also have an asparagine residue at this position [7], as they are inhibited upon binding of a second zinc ion. However, it was demonstrated by Bebrone et al. [30] that this inhibition results from immobilization of the catalytically important His118 and His196 residues. 
Our results differ from those obtained for the GOB-18 variant, which is supposed to be fully active with a single zinc ion in the DHH zinc binding site  ADDIN EN.CITE [18]. GOB-1 and GOB-18 enzymes only differ by three point mutations apparently far from the active site (Leu94Phe, Ala137Val and Asp282Asn) which makes the difference in behaviour between these enzymes difficult to explain. GOB-18 was overproduced as a fusion to GST in the cytoplasm of E. coli and contained significant amounts of zinc and iron (0.45–0.75 iron/GOB-18 and 0.01–0.20 zinc/GOB-18). Only the mono-zinc form of GOB-18 could be obtained by remetallisation of the apo-protein. Its activity largely exceeded that of the GOB-18 enzyme as isolated and addition of zinc did not modify the kinetic parameters  ADDIN EN.CITE [18], further work by the same authors showed the periplasmic enzyme to contain only zinc ions but the number remained unmeasured [18, 34]. In contrast, the protocol of production and purification described here, which uses the enzyme own signal peptide, produces GOB-1 as a fully active di-zinc enzyme. We have also shown that it possible to reconstitute a binuclear GOB-1 from the metal-depleted enzyme by using similar procedure to that previously described [18]. Furthermore, the Q116A and Q116N mutants which had lost the zinc in the “QHH” site showed a significantly decreased activity compared to that of the wild-type enzyme, the difference in both kcat and the zinc content can only be accounted for by a single amino acid change if this is a zinc binding residue. 






Buffers and BSA were purchased from BDH Chemicals (Poole, UK) or Sigma-Aldrich (Steinheim, Germany); isopropyl--D-thiogalactopyranoside (IPTG) from Eurogentech (Liège, Belgium) and Kanamycin, DMSO and ZnCl2 from Merck (Darmstadt, Germany). Meropenem (Δε300 = -6500 M-1cm-1) was a gift from ICI Pharmaceuticals (Macclesfield, England). Imipenem (Δε300 = -9000 M-1cm-1) was a gift from Merck Sharpe and Dohme Research Laboratories (Rahway, NJ, USA). Benzylpenicillin (Δε235 = -775 M-1cm-1) was a gift from Rhône-Poulenc (Paris, France). Chloramphenicol, cefoxitin (Δε260 = -6600 M-1cm-1), cephalothin (Δε273 = -6300 M-1cm-1), EDTA were purchased from Sigma (St Louis, MO, USA) and nitrocefin (Δε482 = 15000 M-1cm-1) from Unipath Oxoid (Basingstoke, UK). Sequencing grade modified trypsin was obtained from Promega (Madison, WI, USA) and α-cyano-4-hydroxycinnamic acid was from Aldrich (Taufkirchen, Germany). The peptide standard mixture was purchased from Applied Biosystems.

Bacterial strains and vectors
The plasmid pBS3 has been described previously. E. coli DH5α was used as the host for recombinant plasmids during the construction of the expression vectors. E. coli BL21-DE3 and E. coli BL21-DE3 (pLysS) (Novagen Inc., Madison, Wisconsin) were both tested as the hosts for the expression plasmids. The expression vector pET28a (Novagen) was used for the construction of the T7-based expression factor. 

Construction of expression vector and preliminary expression experiments
BamH1 and Xho1 restriction sites were introduced at either end of the blaGOB-1 gene by PCR using the oligonucleotide primers (5’-GGGGGGGGATCCATGAGAAATTTTGCTACACTGTTTTTCATG-3’) and (5’-CCCCCCCTCGAGTTATTTATCTTGGGAATCTTTTTTTATTTTGTC-3’), where the restriction sites generated are underlined. The PCR conditions were: incubation at 95 C for 5 min; 30 cycles of amplification that involved denaturation for 1 min at 95 C, annealing for 1 min at 58 C and extension for 1 min at 68 C; and 5 min at 68 C after the cycling. Pfu and taq polymerase (from Promega, Madison, USA) were used for the PCR. The PCR products were cloned into the pET28a vector to obtain the recombinant plasmid pGB1, which was then transformed into E. coli DH5α. The gene was sequenced to verify that no unwanted mutations had taken place during the PCR.
The pGB1 vector was transformed into E. coli BL21-DE3 and BL21-DE3 (pLysS). Preliminary expression trials involved single colonies of E. coli BL21-DE3 and BL21-DE3 (pLysS) containing pGB1 used to inoculate 100 ml LB, containing 50 g/ml kanamycin. The cultures were incubated overnight at 37 C with orbital shaking at 250 rpm before 2 ml samples were removed and added to 100 ml of medium. 3 types of media, 2XYT, TB and LB, supplemented with 50 g/ml kanamycin were tested. After selection of the best medium, additional conditions were studied; 2 temperatures (28 C and 37 C) and, when the culture reached an absorbance of 0.6 at 600nm, 3 different IPTG concentrations (0, 0.1 and 1 mM). 2 ml aliquots of the various cultures were sampled after 2, 4, 6, 24, 33 and 48 hr. After centrifugation for 1 min at 15,000 x g, the bacterial pellet was resuspended in 500 µl of buffer (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 20 mM at pH 6.5 containing 50 M ZnCl2). Cells were lysed by sonication on ice, which involved 5 x 15 s pulses with 30 s delays. The cell debris were removed by centrifugation at 15,500 x g for 10 min at 4 °C. A 15 l sample from each aliquot was analyzed by SDS PAGE. 
The enzyme activity in each sample was determined by following the hydrolysis of 100 µM imipenem at 300 nm in 20 mM HEPES at pH 6.5 containing 50 M ZnCl2 using a Uvikon XL spectrophotometer and 10 mm path length cells.

Mutagenesis
The Quick Change site-directed mutagenesis kit (Stratagene, La Jolla, California) was used to perform the mutagenesis on the pGB1 plasmid. The primers used for this experiment were as follows: 
For the Q116A mutant forward and reverse:
(5’-GATCTTGCTGCTTACTGCGGCTCACTACGACCATACAGG-3’) 
(5’-GCACCTGTATGGTCGTAGTGAGCCGCAGTAAGCAGC-3’)
For the Q116N mutant forward and reverse:
(5’-GATCTTGCTGCTTACTAACGCTCACTACGACCATACAGG-3’) 
(5’-GCACCTGTATGGTCGTAGTGAGCGTTAGTAAGCAGC-3’)




Production and purification of the zinc -lactamase
100 ml of LB medium, containing 50 g/ml kanamycin, were inoculated with a colony of E. coli BL21-DE3 carrying the pGB1 plasmid and incubated overnight at 37 C with orbital shaking at 250 rpm. 20 ml of preculture were added to 2 l of TB medium and incubated at 28 C for 24 hr under orbital shaking. Cells were harvested by centrifugation at 14,500 x g, for 20 min, at 4 C. The pellet was resuspended in 200 ml of buffer A (20 mM sodium cacodylate, pH 6.5) before the cells were disrupted (Basic Z model; Constant Systems Ltd., Warwick, UK). Cell debris were removed by centrifugation at 14,300 x g, for 40 min, at 4 C and the supernatant dialyzed overnight against buffer A at 4 C. The crude extract was then loaded onto an S-Sepharose FF column (2.6 by 34 cm; Pharmacia, Uppsala, Sweden) equilibrated in buffer A. The column was washed with buffer A before a salt gradient of 0 to 0.5 M NaCl in 5 column volumes was used to elute the GOB-1 protein. The active fractions were pooled and dialyzed overnight against buffer A to remove the salt. The sample was loaded onto an UNO S-12 column equilibrated with buffer A and eluted with a 0 to 0.5 M NaCl gradient in 5 column volumes. The fractions that showed -lactamase activity were then loaded onto a Sephacryl-100 molecular sieve column (1.5 by 56 cm) previously equilibrated in buffer B (buffer A with 0.25 M NaCl). For molecular mass determination on this column, the following proteins were used for calibration; BSA 66.2 kDa, ovalbumin 45 kDa, soybean trypsin inhibitor 21.5 kDa, lysozyme 14.4 kDa. Active fractions were pooled, dialyzed against buffer A and concentrated to a final concentration of approximately 1 mg/ml, before being stored at – 20°C.
The mutant plasmids were transformed into E. coli BL21-DE3 and production was carried out as described above for the wild type. Purification was performed as described for the wild type with the following modifications. The second column used was a 5 ml ceramic hydroxyapatite Econo-Pac CHT-II cartridge from Bio-Rad (the purification was performed as suggested in the instructions). The third column, an S-Source column from Amersham Biosciences, was used to separate the desired mutants from the variant of the enzyme with an N-terminal pyro-glutamate residue. The enzyme was loaded and the column was washed in 20 mM sodium cacodylate pH 6.5 before a salt gradient of 0 to 0.5 M NaCl in 10 column volumes was used to elute the GOB-1 mutant.

Mass spectrometry and determination of N-terminal sequence
- Native or denatured intact enzyme
Enzyme samples were desalted using Microcon YM-10 (10 kDa) centrifugal filters (Millipore, UK) in 15 mM ammonium acetate (pH 7.5). Seven dilution/concentration steps were performed at 4 °C and 14,000 g. This yielded a 100 µM stock enzyme solution in ammonium acetate pH 7.5. The experimental samples were then prepared by diluting the enzyme to a final concentration of 15 µM in 15 mM ammonium acetate pH 7.5 directly in a 96 well-plate. ESI-MS analyses used a Q-TOF mass spectrometer (Q-TOFmicro Micromass, Altrincham, UK) interfaced with a NanoMateTM chip-based nano-ESI source (Advion Biosciences, Ithaca, NY, USA). Samples were infused into the Q-TOF through the ESI chip (estimated flow rate 100 nL/min). Typically a spraying voltage of 1.70 kV ± 0.1 kV depending on the "sprayability" of the sample and a sample pressure of 0.25 psi were applied. The instrument was equipped with a standard Z-spray source block. Clusters of Cs(n+1)In (1 mg/ml CsI in 100 % methanol) were used for calibration. Calibration and sample acquisitions were performed in the positive ion mode in the range of m/z 500-5000. Operating conditions for the mass spectrometer were: sample cone voltage 50 V, 80 V and 200 V, source temperature 40°C. Acquisition and scan times were 20 s and 1 s, respectively. The pressure at the interface between the atmospheric source and the high vacuum region was fixed at 6.6 mbar (measured with the roughing pump Pirani gauge) by throttling the pumping line using an Edwards Speedivalve to provide collisional cooling. 

- Peptide mapping
After denaturation at 100 °C for 15 min, 10 µg of GOB-1 was digested with 0.5 µg trypsin in 50 mM NH4HCO3 (pH 8) for 4 hours at 37 °C. The digestion was stopped by adding 0.1 % trifluoroacetic acid. 10 µl of digested protein was loaded on a ZipTip C18 (Millipore Corp., USA). Elution was performed with 10 µl matrix solution (α-cyano-4-hydroxycinnamic acid in 50 % acetonitrile, 0.1 % trifluoroacetic acid) on a MALDI plate and dried before the MALDI measurement.
Mass spectrometric analysis was performed using a 4800 MALDI TOF/TOFTM analyser  (Applied Biosystems / MDS SCIEX) equipped with a 200-Hz Nd:YAG-Laser (λ = 355 nm, 3 to 7 ns pulse width). MS data were acquired in the positive ion reflectron mode with 470-ns delayed extraction, accumulating 500 laser shots using the 4000 Series ExplorerTM Remote Access Client software (version 3.5.1). External mass calibration was performed in the mass range m/z of 800-3500. The calibration mixture consisted of the following compounds: des-Arg1-Bradykinin [904.4681], Angiotensin I [1296.6853], Glu1-Fibrinopeptide B [1570.6774], Adrenocorticotropic hormone fragments 1-17 [2093.0867], Adrenocorticotropic hormone fragments 18-39 [2465.1989], Adrenocorticotropic hormone fragments 7-38 [3557.9294]. For MS/MS measurements, the acceleration voltage was 8 kV, the laser energy 4090 and 4000 laser shots were accumulated. 

- N-terminal sequence
The N-terminal sequence was determined using a gas-phase sequencer (Prosite 492 protein sequencer; Applied biosystems, Foster city, California).

Determination of the zinc and iron content using ICP/MS
Protein samples were dialyzed against 20 mM sodium cacodylate, pH 6.5. Protein concentrations were then determined by standard colorimetric assays (BCA; Pierce, Rockford, Ill.). Zinc and iron concentrations were measured by inductively coupled plasma mass spectroscopy (ICPMS) at the Malvoz Institute (Province de Liège, Belgium). The metal/enzyme ratio was calculated from the differences of metal concentration between the enzyme sample and the dialysis buffer.

Determination of kinetic parameters
Hydrolysis of antibiotics by the wild-type and mutant GOB-1 was monitored by following the variation in absorbance using a Uvikon 860 spectrophotometer connected to a microcomputer via an RS232 serial interface or a Uvikon XL spectrophotometer. Reactions were performed in thermostatically controlled 10 mm and 2 mm path length cells at 30 C and using 20 mM sodium cacodylate buffer pH 6.5, containing 20 g/ml BSA (and 50 M ZnCl2 when indicated). The steady-state kinetic parameters were determined under initial rate conditions using the Hanes linearization of the Henri-Michaelis-Menten equation. Low KM values were determined as Ki’s using meropenem as reporter substrate. In these cases, the kcat values were obtained from initial hydrolysis rates measured at saturating substrate concentrations. All data were analyzed using Microsoft Excel and the KaleidaGraph 3.5 programme [36]. 

Enzymatic measurement in the presence of increasing concentrations of zinc and determination of KD2
Activity was measured in the presence of increasing concentrations of zinc at 30°C in 20 mM sodium cacodylate buffer pH 6.5, containing 20 g/ml BSA as already described. The binding of the second zinc ion resulted in an increase of activity and Equation 1 was used:
RA = [(KD2+[Zn])/([Zn]+KD2)]	
where  represents the ratio of activity at saturating zinc concentration versus activity in the absence of added zinc (Act. [Zn](∞) / Act. [Zn](0) ).
Experimental data were fitted to Equation 1 by non-linear regression analysis with the help of the Sigma Plot software.

Preparation of the GOB-1 apoenzyme and the remetallated form
The GOB-1 apoprotein was prepared by treating ~ 40 µM enzyme samples in 10 mM Tris-HCl, pH 7.0, with chelating agents in mild denaturing conditions, as previously described for GOB-18 [18]. The remetallated form was obtained by dialyzing the apo-GOB-1 against 100 volumes of 10 mM Tris-HCl, pH 7.0, 50 mM NaCl, with 40 µM ZnSO4.

Inactivation by chelating agents
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Figure S1. GOB-1 sequence, including the LNA from the signal peptide. Peptides from the tryptic digestion identified by MALDI-TOF MS are highlighted to show the sequence coverage. Peptides either have one or no site of missed cleavage, no peptides with 2 or more missed cleavage sites were identified.
Figure S2. Relative activity of the Q116N mutant measured in the presence of increasing concentrations of zinc. 
Figure S3. Native ESI-TOF mass spectra of the remetallated GOB-1.




Table 1. Masses of the wild-type and mutant enzymes measured by ESI-TOF MS and calculated from their amino acid sequences.









Table 2. Summary of zinc binding for wild-type and mutants GOB-1. 
SD values were below 10%. 









Table 3. The steady-state kinetic parameters for the GOB-1 wild-type and mutants Q116A, Q116N and Q116H, both in the presence and in the absence of added 50 µM ZnCl2.
	50 µM zinc	no added zinc
	KM (µM)	kcat (s-1)	kcat/KM  (µM-1s-1)	KM (µM)	kcat (s-1)	kcat/KM    (µM-1s-1)
	Wild-type
Imipenem	13  1	85  2	6.5	18  0.6	77  2	4.2
Meropenem	22  1	170  3	8.0	29  1	100  7	3.5
Benzylpenicillin	190  10	630  10	3.4	130  6	540  7	4.2
Nitrocefin	16  3	14  0.5	0.87	7.1  0.2	20  2	2.8
Cephalothin	7.9  0.5	32  0.4	4.0	3.8  0.1	24  0.7	6.5
Cefoxitin	8.9  1	9.6  0.4	1.1	1.4  0.04	3.5  0.3	2.6
	Q116A
Imipenem	720  100	2.3  0.2	0.0032	21  0.9	0.50  0.005	0.024
Meropenem	130  20	1.1  0.05	0.0088	34  3	0.62  0.02	0.018
Benzylpenicillin	410  40	4.6  0.1	0.011	96  10	1.9  0.08	0.020
Nitrocefin	30  4	0.12  0.002	0.0038	13  1	0.080  0.003	0.0062
Cephalothin	42  4	0.61  0.01	0.015	15  0.7	0.16  0.002	0.011
Cefoxitin	78  10	0.21  0.009	0.0027	7.2  0.09	0.31  0.01	0.043
	Q116N
Imipenem	42  4	3.8  0.1	0.025	69  6	0.95  0.03	0.014
Meropenem	20  2	1.5  0.03	0.074	31  3	0.44  0.01	0.014
Benzylpenicillin	140  10	22  0.5	0.16	200  10	4.9  0.1	0.025
Nitrocefin	360  60	11  0.9	0.031	210  40	0.86  0.06	0.0041
Cephalothin	4.7  0.1	1.2  0.05	0.25	37  4	0.16  0.004	0.0044
Cefoxitin	10  0.3	0.16  0.01	0.016	2.3  0.1	0.026  0.003	0.011
	Q116H
Imipenem	170  20	21  0.7	0.13	150  10	17  0.5	0.12
Meropenem	25  3	2.3  0.07	0.089	17  2	2.0  0.05	0.11
Benzylpenicillin	790  40	300  6	0.38	850  60	280  7	0.33
Nitrocefin	43  6	3.5  0.1	0.080	43  4	1.6  0.05	0.038
Cephalothin	64  4	9.9  0.2	0.15	57  6	8.0  0.3	0.14




Figure 1. ESI-TOF mass spectrum of wild-type GOB-1 showing the presence of 2 protein peaks separated by about 300 Da.

Figure 2. Peptide mass fingerprint of GOB-1 digested by trypsin for 4 hours. (inset: N-terminus modified peptide with mass accuracy of 10 ppm)

Figure 3. Superimposed ESI-TOF mass spectra of the two active peaks produced during the final step of purification of the Q116H mutant.

Figure 4. Native ESI-TOF mass spectra of the wild-type and mutant GOB-1. 
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